Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.545 CHF -1.94% Market Closed
Market Cap: 183.4m CHF

Relative Value

The Relative Value of one MOLN stock under the Base Case scenario is 2.905 CHF. Compared to the current market price of 4.545 CHF, Molecular Partners AG is Overvalued by 36%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MOLN Relative Value
Base Case
2.905 CHF
Overvaluation 36%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
53
vs Industry
36
Median 3Y
11.1
Median 5Y
21.9
Industry
7.6
Forward
31.7
vs History
vs Industry
13
Median 3Y
-1.8
Median 5Y
-3
Industry
21.3
Forward
-2.8
vs History
vs Industry
14
Median 3Y
-2.4
Median 5Y
-3.5
Industry
21.2
vs History
vs Industry
10
Median 3Y
-2.3
Median 5Y
-3.4
Industry
23.9
vs History
52
vs Industry
57
Median 3Y
1
Median 5Y
1.4
Industry
2.5
vs History
50
vs Industry
70
Median 3Y
-0
Median 5Y
5.1
Industry
7.3
Forward
4.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.7
vs History
vs Industry
20
Median 3Y
-0.1
Median 5Y
-0.7
Industry
4.4
Forward
-0.6
vs History
vs Industry
18
Median 3Y
-0.1
Median 5Y
-0.7
Industry
4.3
Forward
-0.5
vs History
vs Industry
22
Median 3Y
-0.1
Median 5Y
-0.8
Industry
6
vs History
vs Industry
18
Median 3Y
-0.1
Median 5Y
-0.8
Industry
4
vs History
52
vs Industry
41
Median 3Y
-0.2
Median 5Y
7
Industry
4.4

Multiples Across Competitors

MOLN Competitors Multiples
Molecular Partners AG Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Molecular Partners AG
SIX:MOLN
183.4m CHF 17.6 -2.7 -0.4 -0.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 733 989 -184 096.9 -223 552.2 -221 001.2
US
Abbvie Inc
NYSE:ABBV
313.6B USD 5.6 61.7 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
144.4B USD 4.4 34.1 16.3 30.8
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.7 9.9 9.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.4B USD 9.8 -217.5 21.4 22.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 818.8 -464.1 -505.4 -491.9
AU
CSL Ltd
ASX:CSL
135.3B AUD 5.6 31.5 19.5 24.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.6B USD 5.6 16.7 15.1 16.8
US
Seagen Inc
F:SGT
39.3B EUR 17.5 -53.7 -57.7 -52.1
NL
argenx SE
XBRU:ARGX
38.2B EUR 17.9 -346.8 -164.9 -107.4
P/S Multiple
Revenue Growth P/S to Growth
CH
Molecular Partners AG
SIX:MOLN
Average P/S: 3 521 445.1
17.6
42%
0.4
FR
Pharnext SCA
OTC:PNEXF
38 733 989
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
6%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.4
8%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
4
3%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
1 818.8
N/A N/A
AU
CSL Ltd
ASX:CSL
5.6
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
7%
0.8
US
S
Seagen Inc
F:SGT
17.5
30%
0.6
NL
argenx SE
XBRU:ARGX
17.9
53%
0.3
P/E Multiple
Earnings Growth PEG
CH
Molecular Partners AG
SIX:MOLN
Average P/E: 207.1
Negative Multiple: -2.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -184 096.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.7
72%
0.9
US
Amgen Inc
NASDAQ:AMGN
34.1
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
891.7
21%
42.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -217.5
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -464.1 N/A N/A
AU
CSL Ltd
ASX:CSL
31.5
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -346.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Molecular Partners AG
SIX:MOLN
Average EV/EBITDA: 16.3
Negative Multiple: -0.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -223 552.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16.3
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.4
13%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.4 N/A N/A
AU
CSL Ltd
ASX:CSL
19.5
12%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -164.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Molecular Partners AG
SIX:MOLN
Average EV/EBIT: 21.3
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -221 001.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.8
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -491.9 N/A N/A
AU
CSL Ltd
ASX:CSL
24.4
16%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -107.4 N/A N/A